Evidence map›Paper›PMID 30903304›Full record

ArticleJournal of cheminformatics2019

Binding mode information improves fragment docking.

Célien Jacquemard, Malgorzata N Drwal, Jérémy Desaphy, Esther Kellenberger

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Biased Docking for Protein-Ligand Pose Prediction.Methods in molecular biology (Clifton, N.J.) · 2021
    Article
  7. Review
  8. Frontiers in chemistry · 2020
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Célien JacquemardLaboratoire d'innovation thérapeutique, UMR7200, CNRS, Université de Strasbourg, 67400, Illkirch, France.
Malgorzata N DrwalLaboratoire d'innovation thérapeutique, UMR7200, CNRS, Université de Strasbourg, 67400, Illkirch, France.
Jérémy DesaphyLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA.
Esther KellenbergerLaboratoire d'innovation thérapeutique, UMR7200, CNRS, Université de Strasbourg, 67400, Illkirch, France. ekellen@unistra.fr.ORCID http://orcid.org/0000-0002-9320-4840

Funding

Eli Lilly and Company LRAP funding program
6 · The paper itself

Abstract

Docking is commonly used in drug discovery to predict how ligand binds to protein target. Best programs are generally able to generate a correct solution, yet often fail to identify it. In the case of drug-like molecules, the correct and incorrect poses can be sorted by similarity to the crystallographic structure of the protein in complex with reference ligands. Fragments are particularly sensitive to scoring problems because they are weak ligands which form few interactions with protein. In the present study, we assessed the utility of binding mode information in fragment pose prediction. We compared three approaches: interaction fingerprints, 3D-matching of interaction patterns and 3D-matching of shapes. We prepared a test set composed of high-quality structures of the Protein Data Bank. We generated and evaluated the docking poses of 586 fragment/protein complexes. We observed that the best approach is twice as accurate as the native scoring function, and that post-processing is less effective for smaller fragments. Interestingly, fragments and drug-like molecules both proved to be useful references. In the discussion, we suggest the best conditions for a successful pose prediction with the three approaches.

Indexed as

Docking poseFragment-based drug design (FBDD)Ligand/protein complexScoring

Identifiers

PMID30903304
PMCPMC6431075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.